Predominant functional activity of the large, neutral amino acid transporter (LAT1) isoform at the cerebrovasculature
- PMID: 11403943
- DOI: 10.1016/s0304-3940(01)01810-9
Predominant functional activity of the large, neutral amino acid transporter (LAT1) isoform at the cerebrovasculature
Abstract
In this study, we identify the predominant functional expression of the large, neutral amino acid transporter (LAT1) isoform at the blood-brain barrier (BBB). An in situ rat brain perfusion technique allowed perfusion of the radiotracer [(14)C]-L-Leu (a ligand for both LAT1 and LAT2) alone or competed with excess concentration of either LAT1 or LAT2 specific amino acids. The LAT2 specific amino acid, [(14)C]-L-Asn, was perfused alone or with excess concentration of various amino acids. The brain uptake of [(14)C]-L-Leu was not significantly inhibited by LAT2 specific amino acids, but was inhibited significantly (up to 90%) by the LAT1 specific amino acid, D-Met. L-Asn did not demonstrate saturable brain uptake. These data clearly demonstrate that LAT1 is the functionally predominant isoform expressed at the BBB which is responsible for brain uptake of large, neutral amino acids. In addition, the functional activity of cerebrovascular LAT2 is insignificant, or absent.
Similar articles
-
The 4F2hc/LAT1 complex transports L-DOPA across the blood-brain barrier.Brain Res. 2000 Oct 6;879(1-2):115-21. doi: 10.1016/s0006-8993(00)02758-x. Brain Res. 2000. PMID: 11011012
-
Molecular and functional identification of large neutral amino acid transporters LAT1 and LAT2 and their pharmacological relevance at the blood-brain barrier.J Pharm Pharmacol. 2001 Apr;53(4):497-503. doi: 10.1211/0022357011775794. J Pharm Pharmacol. 2001. PMID: 11341366
-
Expression of a system L neutral amino acid transporter at the blood-brain barrier.Neuroreport. 2000 Nov 9;11(16):3507-11. doi: 10.1097/00001756-200011090-00021. Neuroreport. 2000. PMID: 11095508
-
Exchange-mode glutamine transport across CNS cell membranes.Neuropharmacology. 2019 Dec 15;161:107560. doi: 10.1016/j.neuropharm.2019.03.003. Epub 2019 Mar 8. Neuropharmacology. 2019. PMID: 30853601 Review.
-
[Amino acid transporter molecule as a drug target].Nihon Yakurigaku Zasshi. 1999 Oct;114 Suppl 1:11P-16P. doi: 10.1254/fpj.114.supplement_11. Nihon Yakurigaku Zasshi. 1999. PMID: 10629848 Review. Japanese.
Cited by 29 articles
-
Targeting Transporters for Drug Delivery to the Brain: Can We Do Better?Pharm Res. 2022 Jul;39(7):1415-1455. doi: 10.1007/s11095-022-03241-x. Epub 2022 Mar 31. Pharm Res. 2022. PMID: 35359241 Free PMC article. Review.
-
Metabolic Features of Brain Function with Relevance to Clinical Features of Alzheimer and Parkinson Diseases.Molecules. 2022 Jan 30;27(3):951. doi: 10.3390/molecules27030951. Molecules. 2022. PMID: 35164216 Free PMC article. Review.
-
A Novel Blood-Brain Barrier-Permeable Chemotherapeutic Agent for the Treatment of Glioblastoma.Cureus. 2021 Aug 31;13(8):e17595. doi: 10.7759/cureus.17595. eCollection 2021 Aug. Cureus. 2021. PMID: 34646647 Free PMC article.
-
Peptide-Based Strategies for Targeted Tumor Treatment and Imaging.Pharmaceutics. 2021 Apr 2;13(4):481. doi: 10.3390/pharmaceutics13040481. Pharmaceutics. 2021. PMID: 33918106 Free PMC article. Review.
-
Oral administration of Cystine and Theanine ameliorates oxaliplatin-induced chronic peripheral neuropathy in rodents.Sci Rep. 2020 Jul 29;10(1):12665. doi: 10.1038/s41598-020-69674-9. Sci Rep. 2020. PMID: 32728157 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
